Kennedy Capital Management, Inc. Cytom X Therapeutics, Inc. Transaction History

Kennedy Capital Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$7.4 - $14.64 $600,850 - $1.19 Million	-81,196 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.61 - $8.6 $41,359 - $98,530	11,457 Added 16.43%	81,196 $623,000
Q4 2019 Feb 14, 2020	SELL	$5.17 - $8.91 $3,463 - $5,969	-670 Reduced 0.95%	69,739 $580,000
Q3 2019 Nov 14, 2019	SELL	$7.38 - $12.25 $37,623 - $62,450	-5,098 Reduced 6.75%	70,409 $520,000
Q2 2019 Aug 14, 2019	BUY	$9.35 - $11.41 $705,990 - $861,534	75,507 New	75,507 $847,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.